Objective:
To report on the FDA's complete response letter regarding SYD-101, a low-dose atropine formulation for pediatric myopia.
Approach:
- Study Overview: The NDA for SYD-101 was supported by phase III results from the STAR trial, which involved approximately 847 children with myopia.
- Regulatory Status: The European Medicines Agency granted a positive opinion for SYD-101 based on the STAR trial data.
Key Findings:
- SYD-101 met its primary efficacy endpoint in the STAR trial.
- The FDA acknowledged no safety concerns but questioned the efficacy of low-dose atropine for myopia treatment.
Interpretation:
Limitations:
- The FDA's CRL suggests that current data does not sufficiently support the efficacy claims for SYD-101.
Conclusion:
Sydnexis plans to work with the FDA to address the concerns raised in the CRL.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
